Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Onasemnogene Abeparvovec-xioi · 5 trials · 7 indications
Assessed via the developmental milestone checklist, formed of 10 yes/no questions. The developmental milestones are: head control, sitting with support, sitting without support, sitting without support for 30 seconds, hands-and-knees crawling, pulls to stand, standing with assistance, walking with assistance, standing alone and walking alone.
The HFMSE was devised for use in children with SMA to give objective information on motor ability and clinical progression. The HFMSE is formed of 33 assessments rated from 0 (unable to perform functional task) to 2 (able to perform functional task unassisted). Higher scores on the total scale of 0-66 indicates higher levels of motor ability.
Participants will receive pulmonary assessments by a pulmonologist or appropriate clinician. Respiratory device data will be reviewed for participants receiving non-invasive ventilatory support.
Assessed via the swallowing function questionnaire, formed of 4 yes/ no questions and 1 body weight question.
The physical examination includes review of the following systems: head, ears, eyes, nose and throat, lungs/thorax, cardiovascular, abdomen, musculoskeletal, neurologic, dermatologic, lymphatic, and genitourinary. In addition, visual inspection of the spine, back, shoulders, and hips looking for spinal curvature and asymmetry will be carried out. Joints will be assessed for loss of mobility and contractures.
Vital sign measurements will include blood pressure, respiratory rate, pulse, axillary temperature, and pulse oximetry.
Blood samples will be collected for hematology (including complete blood cell count) and chemistry.
Cardiac assessments will include a 12-lead electrocardiogram, transthoracic echocardiogram and Troponin-I.
The observational phase questionnaire includes 7 yes/no questions. Observation categories include: adverse events, hospitalizations, concomitant medications, ventilatory support and feeding support.
An SAE is defined as any adverse event (appearance of \[or worsening of any pre existing\]) undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria: * Fatal * Life-threatening * Results in persistent or significant disability/incapacity * Constitutes a congenital abnormality or birth defect * Requires in-patient hospitalization or prolongation of existing hospitalization * Is medically significant e.g. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above
An AESI is defined as an AE occurring during any study phase that fulfills one of the following criteria: * Hepatotoxicity * Thrombotic microangiopathy * Cardiac adverse events * Dorsal root ganglia toxicity * New malignancies * New incidence of a neurologic disorder * New incidence of an autoimmune disorder * New incidence of hematologic disorder
Third Edition (Bayley-III) to be performed in all patients up to 42 months, 15 days of age.
RULM score is based on a scale from 0 to 37 where lower scores reflect poorer upper limb functional ability.
The Cogstate Computerized Cognitive Battery consists of the Identification Test (scored 0 (best) to 1.5708 (worst)), the International Shopping List Test (scored 0 (worst) to 999 (best)), the International Shopping List Test-Delayed Recall (scored 0 (worst) to 999 (best)), the One Card Learning Test (scored 0 (worst) to 1.5708 (best)), and the One Back Test (scored 0 (worst) to 1.5708 (best)).
The CELF-5 Following Directions and Sentence Repetition subtests use scoring that varies based on age, but will be administered to participants 5-21 years of age. The Following Directions subtest will be scored from 0-33 with higher score being more advanced and the Recalling Sentences subtest will be scored from 0-78 with higher score being more advanced.
ACEND score is based on a scale from 1 to 41 where higher scores represent a better caregiver experience
Independent sitting is defined by the World Health Organization Multicentre Growth Reference Study, confirmed by video recording, as a participant who sits up straight unsupported for at least 10 seconds.
Independent sitting is defined by the World Health Organization Multicentre Growth Reference Study, confirmed by video recording, as a participant who sits up straight with head erect for at least 10 seconds; participant does not use arms or hands to balance body or support position.
Defined by the Bayley Scales of Infant and Toddler Development (BSID) Gross Motor (GM) subtest performance criteria number 26, confirmed by video recording, as a participant who sits for at least 30 seconds without assistance from another person or object. The participant was allowed to use their upper extremities.
Defined by the BSID GM subtest performance criteria number 40, confirmed by video recording, as a participant who stands alone for at least 3 seconds unsupported.
Independent sitting is defined as sitting up straight with head erect for at least 30 seconds. This endpoint is a co-primary endpoint. The two co-primary efficacy endpoints were assessed in sequence: The endpoint of functional independent sitting was assessed first and, only when this assessment met statistical significance, was the endpoint of event-free survival assessed.
Survival is defined by the avoidance of combined endpoint of either death or permanent ventilation, which is defined by tracheostomy or by the requirement of ≥ 16 hours of respiratory assistance per day for ≥ 14 consecutive days in the absence of an acute reversible illness, excluding perioperative ventilation. Permanent ventilation is considered a surrogate for death. An acute reversible illness is defined as any condition other than SMA that results in increased medical intervention. The endpoint is a co-primary endpoint. The two co-primary efficacy endpoints were assessed in sequence: The endpoint of functional independent sitting was assessed first and, only when this assessment met statistical significance was the survival endpoint assessed.
| Arm | Type | Description |
|---|---|---|
| Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec-xioi | OTHER | Participants received treatment with IV onasemnogene abeparvovec-xioi in an onasemnogene abeparvovec-xioi or received treatment with IT onasemnogene abeparvovec-xioi in an onasemnogene. |
| Onasemnogene Abeparvovec-xioi | EXPERIMENTAL | Participants will receive a single dose of onasemnogene abeparvovec-xioi, administered intravenously. |
| Name | Type | Description |
|---|---|---|
| Onasemnogene Abeparvovec-xioi | BIOLOGICAL | Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight. |
Inclusion Criteria: * Any participant with SMA who received onasemnogene abeparvovec-xioi gene replacement therapy in a Novartis Gene Therapies-sponsored clinical study * Participant/parent/legal guardian willing and able to complete the informed consent process and comply with study procedures and...
Onasemnogene Abeparvovec-xioi is used for spinal muscular atrophy (SMA), including spinal muscular atrophy type I. It is a gene therapy being developed by Novartis AG for the treatment of SMA, a genetic disorder affecting motor neurons.
Onasemnogene Abeparvovec-xioi is a gene therapy that targets the underlying genetic cause of spinal muscular atrophy by delivering a functional copy of the SMN1 gene. It is classified as a -vec/-gene (gene tx) modality.
Onasemnogene Abeparvovec-xioi is developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker NVS.
Onasemnogene Abeparvovec-xioi is in Phase 3 clinical development. It is an investigational gene therapy and has not been approved by regulatory authorities based on the available information.
Onasemnogene Abeparvovec-xioi has been studied in several Phase 3 trials, including NCT03306277, NCT03461289, NCT03837184, and NCT04042025. These trials enrolled patients with spinal muscular atrophy type I and other SMA types, with a total enrollment of 87 participants across completed and active studies.
Onasemnogene Abeparvovec-xioi is the same as Zolgensma, a gene therapy for spinal muscular atrophy. It is also known by the name AVXS-101 in some contexts.